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Background - Red blood cell (RBC) exchange (RCE) transfusion therapy 
is indicated for certain patients with sickle cell disease (SCD). Although 
beneficial, this therapy is costly and inconvenient to patients, who may 
require it monthly or more often. Identification of blood and plasma 
biomarkers that could improve or help individualise RCE therapy is of interest. 
Here we examined relevant blood and plasma metabolites and biomarkers 
of vasoactivity and RBC fragility in a pilot study of SCD patients undergoing 
RCE using either standard RBC units or RBC units treated with a US Food and 
Drug Administration (FDA)-approved additive solution containing phosphate, 
inosine, pyruvate, and adenine (“PIPA”).
Materials and methods - In this prospective, single-blind, cross-over pilot 
clinical trial, patients were randomised to receive either standard RBC 
exchange or PIPA-treated RBC exchange transfusion with each RCE session 
over a 6-month treatment period. Pre- and post-transfusion blood samples 
were obtained and analysed for RBC O2 affinity, ATP, purine metabolites, RBC 
microparticles, and cell free haemoglobin. 
Results - Red blood cell O2 affinity was maintained after PIPA-RCE in contrast 
to standard RCE, after which P50 fell (net O2 affinity rose). Plasma ATP did not 
change significantly after RCE using either of the RBC unit types. Exchange 
transfusion with PIPA-treated RBC units led to modest increases in plasma 
inosine and hypoxanthine. Plasma cell free haemoglobin fell after either 
standard or PIPA-treated RBC exchange transfusion (novel findings), and to a 
similar extent. RBC-derived microparticles in the plasma fell significantly and 
similarly after both standard and PIPA-treated RCE transfusion. 
Discussion - In summary, treatment of RBCs with PIPA prior to RCE elicited 
favourable or neutral changes in key metabolic and vascular biomarkers. 
Further study of its efficacy and safety is recommended and could ultimately 
serve to improve outcomes in chronically transfused SCD patients. 
Keywords: sickle cell disease, exchange transfusion.
Arrived: 1 October 2019
Revision accepted: 20 December 2019
Correspondence: Tim J. McMahon
e-mail: tim.mcmahon@duke.edu
1Department of Pediatrics, Duke 
University Medical Center, 
Durham, NC; 
2Department of Anesthesiology, 
Duke University Medical Center, 
Durham, NC; 
3Department of Pediatrics, 
University of North Carolina at 
Chapel Hill, Chapel Hill, NC;
4Department of Medicine, Duke 
University Medical Center, 
Durham, NC;
5Department of Pathology, Duke 
University Medical Center, 
Durham, NC;
6Durham Vetern Af fairs
Health Care System,
Durham, NC;
United States of America
Effects of repleting organic phosphates 
in banked erythrocytes on plasma 
metabolites and vasoactive mediators 
after red cell exchange transfusion in 
sickle cell disease
Denise A. Lopez Domowicz1, Ian Welsby2, Charles R. Esther Jr.3, Hongmei Zhu4, 
Robert D. Marek4, Grace Lee4, Nirmish Shah1,4, Jessica L. Poisson5, Tim J. McMahon4,6
Blood Transfus 2020; 18: 200-7  DOI 10.2450/2020.0237-19
adhere to the vascular endothelium4,6. Additionally, 
they are depleted of 2,3-diphosphoglycerate (2,3-
DPG) and adenosine triphosphate (ATP), and have 
lower P50 (ie, higher O2 affinity)7. As RBCs are 
cleared from circulation, they produce additional 
burdens of RBC breakdown byproducts, including 
cell free haemoglobin (CFH) and RBC microparticles 
(RMPs)8-10. RMPs are already elevated in SCD due to 
sickling and haemolysis and can impair vasodilation, 
decrease microcirculatory oxygenation, and damage 
vascular endothelium11-13. Thus, these burdens of 
cleared RBCs exacerbate problems already present 
in this high-risk patient population. Additionally, 
SCD patients who routinely undergo RCE face major 
health care burdens arising from the need for central 
vascular access, transfusion complications, work 
and school absences, and high costs14. 
RBC “rejuvenation” (incubation with “PIPA” additive 
solution, containing phosphate, inosine, pyruvate, 
and adenine) is a US Food and Drug Administration 
(FDA)-approved, standardised blood bank process 
that restores the organic phosphates 2,3-DPG and 
ATP, and raises the P50, all of which are reduced 
during storage15,16. RBC transfusate incubation with 
PIPA increases RBC membrane stress tolerance, and 
microcirculatory oxygenation, while decreasing RMP 
generation and vascular endothelial adhesion17-19. 
In this pilot study, we studied a cohort of clinically 
stable, crisis-free, chronically RCE-transfused SCD 
patients and compared the effects of standard RBC 
exchange transfusion (STD-RCE) vs PIPA-treated 
RBC exchange transfusion (PIPA-RCE) on plasma 
vasoactive biomarkers/mediators. Specifically, we 
examined purine metabolites including and related 
to the vasoactive mediator ATP (which is augmented 
in PIPA-treated RBCs), and the RBC haemolysis 
biomarkers and vasoactive mediators plasma CFH 
and red cell-derived RMPs. Plasma ATP originating 
in RBCs or other cells may act as a vasodilator 
and antiadhesive agent20,21. ATP can also elicit 
pro-inf lammatory effects22. CFH and RMPs ref lect 
the balance between RBC fragility and related 
clearance mechanisms, and may also contribute 
to vascular pathophysiology in SCD or after RBC 
transfusion10. We hypothesise that changes in these 
INTRODUCTION
Sickle cell disease (SCD), the most common inherited 
blood disorder in the United States, is characterised 
by abnormal sickle haemoglobin (HbS) production. 
As a result, the capacity of sickle red blood cells 
(RBCs) to transport and deliver oxygen is impaired. 
In low-oxygen conditions, HbS polymerises, 
altering RBC morphology and susceptibility to lysis 
and triggering recurrent vaso-occlusive episodes 
and pain crises1. Chronic periodic RBC exchange 
transfusion is indicated for patients with SCD for 
primary and secondary stroke prophylaxis and for 
patients with recurrent vaso-occlusive crises2,3. 
Red blood cell exchange (RCE) transfusion is a 
therapeutic intervention in SCD involving the 
removal of native sickle (SS) RBCs in exchange 
for the administration of multiple units of packed 
healthy RBCs. In RCE transfusion, RBCs containing 
normal adult haemoglobin (HbA) are given to largely 
replace the recipient’s diseased HbS-containing 
RBCs and to reach a target clinically determined 
% HbA (e.g. >50%) level. The interval between RBC 
exchanges (typically every 3-6 weeks) is determined 
based in part on the projected rate of HbA clearance. 
This partial exchange of HbS for HbA reduces the 
number of SS RBCs present, lowering viscosity, and 
protecting against sickling and vaso-occlusion2. This 
can in turn reduce the rate of serious complications, 
including recurrent pain crisis, acute chest 
syndrome, stroke, and renal and other end organ 
damage. This intervention is critical in patients with 
SCD who require chronic transfusion for a number of 
indications, including secondary stroke prevention. 
However, the duration of benefit from transfusion 
is limited due, in part, to the clearance over time of 
transfused RBCs, which have already aged during 
storage4. Additionally, large-volume RBC transfusion 
is associated with other complications including 
iron overload, iron-mediated hypercoagulability, 
and progressive development of alloimmunisation, 
motivating the study of determinants of optimal 
RBC unit processing5. 
Transfused RBCs are also substantially altered by 
storage. Refrigerated storage is known to make RBCs 
more rigid, less tolerant of stress, and more likely to 
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to Rejuvesol® RBC Processing Solution (Zimmer 
Biomet Labs, LLC, Braintree, MA, USA), per standard 
protocol24. Brief ly, RBC units are infused with PIPA 
solution for 1 hour at 37 ˚C, washed with saline in a 
Cobe 2991 Cell Washer (TerumoBCT, Lakewood, CO, 
USA), and suspended in 0.9% saline/0.2% dextrose 
for transfusion. The 4-unit treatment was based on 
practical considerations while projecting that this 
would equate to PIPA treatment of a high fraction of 
the patient’s final circulating RBC volume. 
P₅₀ analysis
Whole-blood P50 was analysed before and after either 
standard or PIPA-treated RCE using a TCS Hemox 
analyser (TCS Scientific Corporation, New Hope, PA, 
USA), according to the manufacturer’s instructions.
ATP, purine metabolites, and cell-free haemoglobin 
assays
Plasma from patient samples was analysed for 
ATP concentration, purine metabolites, and CFH. 
ATP was measured using a commercially available 
luciferase ATP assay (Sigma). Purine metabolites 
were measured using a previously described mass 
spectrometric method25. CFH was measured using 
multi-wavelength absorbance spectroscopy for 
haemoglobin, as we described previously26. 
Red blood cell microparticle analysis
Plasma from patient samples was incubated at 
room temperature with RBC-specific CD235a 
antibody (Invitrogen; 1:30 concentration, 50 µL 
samples) for 30 min as previously described to 
distinguish MPs derived from RBCs (RMPs) from 
other microparticles27. The number of RMPs in the 
plasma samples was determined by volumetric 
f low cytometry (Cytek, Aurora, CO, USA). A SCD 
blood sample was used as a positive control to set 
appropriate gates to identify RMPs based on size and 
CD235a staining; these gates were applied to all study 
plasma samples. 
Statistical analysis
All values are reported as means±Standard Error 
of Mean (SE) unless otherwise noted. Outliers were 
defined as ±3 Standard Deviation (SD) from the mean 
in any sample set. No data points fit that criterion, 
and therefore no outliers were excluded. 
biomarkers might therefore provide information on 
the risk-benefit balance of metabolic modification 
of RBCs and ultimately be of benefit in frequently 
transfused SCD patients. 
MATERIAL AND METHODS
Selection and description of research participants
This prospective, single-blind, cross-over pilot 
clinical trial allowed for randomisation of patients 
to receive either PIPA-treated or standard RBC 
exchange transfusion with each treatment session 
over a 6-month treatment period. Other results from 
this study have been published previously23. Eligible 
patients were ≥18 years of age, in stable clinical 
condition, therapy-compliant, chronically transfused 
SCD patients (HbSS) who were maintained with 
repeated RCE therapy and who had been crisis-free 
for a period covering at least the previous three 
consecutive sessions. No patient had tolerated 
chronic hydroxyurea therapy and none received it 
during the study period. Exclusion criteria included 
a baseline need for washed RBCs and pre-treatment 
SaO2 <92%. After written, informed consent under 
a protocol approved by the Duke University Medical 
Center Institutional Review Board, blood samples 
were collected from these established SCD patients. 
Demographic data including age, sex, race, height 
and weight were obtained for each patient. Pre- and 
post-transfusion session vital signs were recorded 
and blood was collected for analysis just before and 
within 60 minutes after RCE. 
Red blood cell units
Per institutional practice, only RBC units stored 
less than 21 days were used for RCE transfusions, 
and all RBC units selected for PIPA exposure 
were stored at least 7 days (after which decreases 
in DPG are substantial). Using standard 
erythocytapheresis, patients received crossmatch-
compatible leukoreduced RBCs that were 
phenotypically matched for at least ABO, D(Rh), C, 
E, and Kell antigens. One patient had additional, 
low-frequency antigens (Lua and Wra) that were easily 
avoided. For standard RCE transfusion, no additional 
manipulations were performed. For sessions in which 
transfusate PIPA treatment (“rejuvenation”) was 
performed, the final 4 units of blood were exposed 
P50 after PIPA-treated RCE transfusion (p=0.0024). 
The interaction between pre vs post P50 effects and 
STD vs PIPA effects was significant by two-way 
ANOVA (p=0.0064).
A mixed error-component statistical model would 
be the ideal approach for the analysis of such data, 
but is not recommended when N <528. Thus, ANOVA 
and t-test analyses were performed using GraphPad 
software version 8.2 (San Diego, CA, USA). p<0.05 
was considered statistically significant. For each 
biomarker, at least one pair of values (pre and post) 
was available for each patient from one STD-RCE 
session and one PIPA-RCE session (n=4 throughout). 
In some cases, data from multiple STD-RCE or 
PIPA-RCE sessions was used for a given patient in 
the principal statistical analysis (n >4).
RESULTS
Demographics
The 4 patients were clinically stable, African-American 
males with HbSS disease, aged 19-32 years; none of 
the patients was currently receiving hydroxyurea. 
They were maintained free from vaso-occlusive crisis 
on a monthly RCE transfusion programme. Based on 
established %HbS targets and patient size, the RBC 
requirements at each RCE session were 7 units for 
3 patients (post-RCE HbA target 75-80%) and 10 units 
for the remaining patient (post-RCE HbA target 
80-85%). Patients underwent up to 3 standard and 
3 PIPA-treated RCE sessions in varying sequence 
over the 6-month study period. The average storage 
age for blood units was 16±5 days for standard units 
and 22±13.5 days for the PIPA-treated units (p=0.002 
vs STD units). Vital signs were stable throughout all 
RCEs, and no transfusion reactions were reported. 
All participants remained crisis-free with stable renal 
function during the study period (data not shown). No 
adverse effects (AEs) of any kind (including serious 
AEs and treatment-emergent AEs) occurred during 
the 4 weeks following the RCE transfusions of either 
standard or PIPA-exposed (rejuvenated) type.
Whole-blood P₅₀
We compared patients' whole-blood P50 before and 
after either a standard RCE transfusion or RCE 
transfusion using PIPA-treated RBCs (Figure 1). The 
P50 decreased after STD transfusion (pre, 28.31±1.6 
vs post,  23.33±1.4)  in  contrast  to  no  change  after  
PIPA-treated RCE transfusion (pre, 28.57±0.4 vs post, 
27.17±1.3). There was improved maintenance of the 
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Plasma ATP
Plasma ATP levels were measured before and after 
either standard or PIPA-treated RCE transfusion. 
There was no greater preservation of ATP in the PIPA-
RCE group post transfusion (Figure 2). There was 
also no overall difference in plasma ATP in pre- vs 
post-RCE transfusion when analysing both transfusion 
conditions (STD-RCE vs PIPA-RCE; p=0.23). There was 
no significant interaction between the pre vs post and 
the STD vs PIPA effects (two-way ANOVA). 
Plasma purine metabolites
To further evaluate the impact of rejuvenation on 
RBC metabolism, we used a mass spectrometric 
method to measure ATP pathway metabolites in 
plasma from a subset of samples pre- and post-
RCE with PIPA-treated RBCs. The primary ATP 
metabolic products, AMP and adenosine, were 
unchanged post transfusion (Figure 3). We observed 
significant increases in plasma inosine (p=0.003), 
a component of Rejuvesol, and in the inosine 
metabolite hypoxanthine (p=0.007) post-PIPA-RCE. 
However, further downstream metabolites including 
adenosine, xanthine and uric acid, were unchanged 
post-PIPA-RCE. 
Figure 1 - P50 before and after standard or phosphate, 
inosine, pyruvate, and adenine (PIPA)-treated red blood 
cell exchange (RCE) transfusion showing improved 
maintenance of P50 with PIPA-treated RCE transfusion 
p=0.0024 for standard (STD)-RCE vs PIPA-RCE. p<0.0001 for Pre vs Post RCE. 
p=0.0064 for interaction of STD-RCE vs PIPA-RCE x Pre vs Post. 
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Figure 2 - Plasma ATP before and after standard (STD) or 
phosphate, inosine, pyruvate, and adenine (PIPA)-treated RCE
Two-way ANOVA was non-significant. In addition, there was no significant effect 
of PIPA and no overall post-red blood cell exchange (RCE) effect on plasma ATP. 
Figure 3 - Mass-spectrometric analysis of plasma obtained 
pre- and post-exchange transfusion of phosphate, inosine, 
pyruvate, and adenine (PIPA)-exposed red blood cells (RBCs) 
Post-transfusion concentrations of inosine (p=0.003) and hypoxanthine 
(p=0.007) increased significantly without changes in other purine metabolites. 
Concentrations are in μM except for uric acid, which is in mM.  
Figure 4 - Plasma cell-free haemoglobin (CFH) before and 
after standard (STD) or phosphate, inosine, pyruvate, and 
adenine (PIPA)-treated red blood cell exchange (RCE)
There is a significant decrease in CFH after both STD and PIPA-treated RCE 
(p=0.047).  
Figure 5 - Plasma red blood cell microparticles (RMPs) before 
and after standard (STD) or phosphate, inosine, pyruvate, 
and adenine (PIPA)-treated red blood cell exchange (RCE)
There is a significant decrease in RMPs after both STD and PIPA-treated RCE 
(p=0.01). 
Plasma cell-free haemoglobin and red blood cell 
microparticles 
Plasma haemoglobin levels were measured pre 
and post either standard or PIPA-treated RCE 
transfusion. Figure 4 demonstrates the nanomolar 
CFH concentration. There is a statistically 
significant decrease in CFH after both STD or PIPA-
treated RCE (p=0.047). There was no significant 
dif ference based on the RCE transfusion type 
(STD-RCE vs PIPA-RCE) in plasma RMPs quantified 
pre and post either standard or PIPA-treated RCE 
transfusion (Figure 5).
There was a statistically significant decrease 
in RMP concentration after RCE transfusion of 
either type (pre vs post, two-way ANOVA with 
post-hoc Bonferroni, p=0.01), but no significant 
difference based on the RCE transfusion type 
(STD-RCE vs PIPA-RCE). 
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DISCUSSION
This pilot study examined the effects of PIPA 
treatment of RBC transfusates on changes in plasma 
metabolic and vasoactive biomarkers in patients 
with SCD requiring chronic RCE transfusion 
therapy. Previous studies have examined metabolic 
changes that develop secondary to RBC storage, but 
few have investigated the metabolic and functional 
changes in the plasma and RBCs of SCD patients 
transfused with metabolically modified RBC units. 
In theory, RBC transfusate modification such as PIPA 
treatment could extend the interval between RCE 
visits and thereby positively inf luence quality of life 
in SCD patients by reducing costs and the incidence 
of complications. We reasoned that a carefully 
controlled demonstration of favourable and safe 
changes in blood biomarkers of RBC metabolism and 
vasoactivity after PIPA-RCE in SCD was warranted 
before such an outcome study.
We found a statistically significant decrease in 
patient blood P50 (increase in RBC Hb O2 affinity) 
after standard RCE transfusion. This finding was 
expected, given that RBCs transfused after storage 
have depressed 2,3-DPG, and thus elevated O2 
affinity (lower P50) relative to fresh (or native HbA) 
RBCs. The P50-lowering effect of RCE was essentially 
eliminated with PIPA-treated RCE transfusion. 
The relative preservation of patient blood P50 using 
stored-RBC exposed to PIPA is not novel, and is 
consistent with the well-established effect of PIPA 
in augmenting stored-RBC organic phosphates (ATP 
and 2,3-DPG)29,30. This corresponds to an increased O2 
off-loading capacity of the PIPA-treated (vs standard) 
transfused RBCs, which may be of clinical benefit 
in this patient population who have physiologically 
compensated for their anaemia by right-shifting 
their O2 dissociation curve at baseline. Specifically, 
SCD patients compensate for their anaemia by 
increasing the production of 2,3-DPG in RBCs, 
in turn lowering RBC O2 affinity (raising the P50). 
Additionally, although RCE transfusion is generally 
beneficial, the overall decrease in P50 (leftward shift 
in the O2-binding curve) resulting from transfusion 
of stored HbA RBCs could limit the potential 
O2-delivery benefits of transfusion, especially in 
SCD patients. In addition, it is possible that O2 
exchange may take place between the transfused 
HbA RBCs (with high O2 affinity) and the native HbS 
RBCs (having low O2 affinity). The net effect could 
be the movement of O2 from low-affinity HbS RBCs 
to high affinity HbA RBCs and a net decrease in 
oxygen delivery from RBCs to the tissue. This could 
promote the sickling of SS RBCs and/or lead to local 
tissue hypoxia. Pre-transfusion PIPA exposure of 
HbA RBCs would tend to attenuate this exchange 
by restoring organic phosphates in the stored RBCs, 
thus moving P50 nearer to that of the native HbS 
RBCs.
Red blood cell exchange  transfusion (both STD-RCE 
and PIPA-RCE) did not significantly alter plasma ATP 
concentration. The plasma ATP may ref lect the net 
balance resulting from the steady-state rates of RBC 
export of ATP and intravascular haemolysis when 
SS RBCs are exchanged for AA RBCs, on one hand, 
and the hydrolysis of ATP on the other20,21. Thus, the 
RBC ATP-repleting effect of PIPA treatment of the 
transfused units may not result in increased ATP 
into the plasma20,21. PIPA treatment of stored RBCs 
does augment ATP export in vitro29, but the net effect 
of transfusion of PIPA-treated RBCs on plasma ATP 
levels in SCD patients may also be driven by a slowing 
of intravascular haemolysis rates (tending to lead to 
lower plasma ATP). Notably, the effects of PIPA on 
post-RCE plasma ATP may have been blunted by the 
fact that the storage age of the PIPA-treated RBC 
units was (by chance) greater than that of the STD 
RBC units used in RCE. 
In our purine analysis, we did not observe any 
changes in plasma adenosine monophosphate 
(AMP) or adenosine (ADO) post-RCE with 
PIPA-treated RBCs, suggesting that ATP metabolism 
was not altered by this process. Plasma ADO is of 
particular interest in terms of safety because it 
can promote pathophysiology in SCD when ADO 
promotes production of 2,3-DPG in erythrocytes, 
which shifts the O2 affinity curve to the right 
(lower P50). This lowered affinity for O2 thus favours 
HbS deoxygenation, RBC sickling, and organ 
dysfunction31. The increased plasma inosine post 
transfusion is consistent with the presence of inosine 
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in PIPA, as was the increase in the inosine metabolite 
hypoxanthine, consistent with our prior findings32. 
Increased plasma hypoxanthine is also a biomarker 
of disease and can contribute to oxidative stress 
through its metabolism by xanthine oxidase32. The 
impact of RCE with PIPA-treated RBCs on oxidative 
stress will need to be determined in future studies. 
In SCD, RMP generation is elevated at baseline 
as a result of accelerated RBC vulnerability and 
turnover33. We found that exchange transfusion 
(standard or PIPA-treated) decreased the overall 
steady-state RMP concentration in SCD patient 
plasma after transfusion, consistent with prior 
reports34,35. We report for the first time that RBC 
exchange transfusion also reduced plasma levels 
of CFH (resulting from intravascular haemolysis) 
regardless of RCE type. Because CFH and RMPs 
can promote intercellular adhesion, blood f low 
dysregulation, and coagulation, all contributing to 
vaso-occlusion and organ damage in SCD, their net 
reduction after RCE is expected to be favourable. 
However, transfused RBC units also contain 
(supernatant) CFH and RMPs, and the amount of 
clearance with RCE would depend in part on the 
RMP content of the transfused units, which may 
vary with factors including RBC storage time (which 
happened to be significantly longer in the PIPA 
group). Finally, the washing that necessarily follows 
PIPA treatment might, on the one hand, “clear” CFH 
and RMPs from the aging RBC unit, but can also 
contribute to generation of CFH and RMPs through 
the added mechanical shear stress of centrifugation 
and osmotic perturbations with washing. It is, 
therefore, reassuring that we observed a net decrease 
in plasma CFH and RMPs, and this favourable effect 
was quantitatively similar in both transfusion types 
(STD-RCE vs PIPA-RCE). 
Collectively, these findings suggest some benefit 
of transfusing PIPA-treated RBCs with a smaller 
post transfusion drop in P50 after rejuvenated 
transfusion. Plasma ATP, exported from RBCs or 
other cells or sources, can act as a regional vasodilator 
and antiadhesive20,21, and so the maintenance of 
ATP concentration after RCE (STD or PIPA) may 
also be reassuring in SCD. Additionally, PIPA-RCE 
demonstrates a similar favourable safety profile to 
STD-RCE with respect to decreased CFH and RMPs 
post transfusion. It also does not appear to contribute 
harmful purine metabolites in the plasma. This 
study is limited, however, in that it is a pilot study 
with a small patient sample. It would be logical in 
future studies to determine whether pre-transfusion 
rejuvenation of stored RBCs, or other strategies 
designed to preserve or replete organic phosphates, 
lead to longer post-transfusion circulating survival 
time after RCE, and to investigate patient-reported 
and clinical outcomes. 
CONCLUSIONS
Chronic RBC transfusion including RCE is a required 
maintenance therapy for many patients with SCD 
and chronic complications. Metabolic optimisation 
of RBC units could extend the interval between RCE 
sessions, would reduce costs and risks, and could 
improve quality of life for SCD patients. As such, 
our findings support further investigation of the 
outcomes of measures to improve the metabolic 
and vasoactive sequelae of RBC transfusions in 
order to improve the risk-benefit balance in chronic 
transfusion therapy for SCD patients. 
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